Rajiv Radhakrishnan, MBBS, MD
- 10Articles
- 104.2KReads1
- 2013–2024Active
- 23Collaborators
- 163Citations2
About
Rajiv Radhakrishnan, MBBS, MD, is affiliated with the Yale Depression Research Program and the Department of Psychiatry at Yale School of Medicine and Yale Psychiatric Hospital. Since 2013, Radhakrishnan has published extensively on topics including addiction, bipolar disorder, psychedelics, psychopharmacology, Alzheimer disease, complementary and alternative medicine, depression, and schizophrenia/schizoaffective disorders. His work covers the clinical application and safety of treatments such as ketamine/esketamine and medical marijuana, as well as the neurobiological effects and therapeutic potential of psychedelics.
Publications
Impact of SUD on COVID-19 Outcomes
August 29, 2022
Psychedelics and Treatment of Psychiatric Disorders, Part 1: Psychopharmacology and Neurobiological Effects
February 23, 2021
Antipsychotics for Homeless and Unstably Housed Veterans
December 8, 2020
1 Read counts for articles published before 2020 may include some non-human traffic.
2 Citation counts provided by Crossref.
Physicians Postgraduate Press, Inc. (PPP) makes no warranties about the accuracy or completeness of any information published in The Journal of Clinical Psychiatry or other PPP materials, and disclaims liability for any use or non-use of that information. Clinicians should not rely solely on these materials and should exercise their own professional judgment when making patient care decisions on an individualized basis.